Clene to Participate at the Benchmark 14th Annual Discovery One-on-One Investor Conference
Clene (Nasdaq: CLNN) announced management will participate in the Benchmark 14th Annual Discovery One-on-One Investor Conference and host 1x1 investor meetings on December 4, 2025 in New York, New York. Meetings are by appointment via Benchmark representatives. The company and its subsidiary Clene Nanomedicine focus on mitochondrial health and neuronal protection for neurodegenerative diseases, including ALS and MS.
Clene (Nasdaq: CLNN) ha annunciato che la direzione parteciperà al Benchmark 14th Annual Discovery One-on-One Investor Conference e ospiterà incontri individuali con gli investitori il 4 dicembre 2025 a New York, New York. Gli incontri avverranno su appuntamento tramite i rappresentanti di Benchmark. L'azienda e la sua controllata Clene Nanomedicine si concentrano sulla salute mitocondriale e sulla protezione neuronale per malattie neurodegenerative, tra cui SLA e SM.
Clene (Nasdaq: CLNN) anunció que la dirección participará en la Benchmark 14th Annual Discovery One-on-One Investor Conference y organizará reuniones 1x1 con inversores el 4 de diciembre de 2025 en Nueva York, Nueva York. Las reuniones serán con cita previa a través de los representantes de Benchmark. La empresa y su filial Clene Nanomedicine se enfocan en la salud mitocondrial y la protección neuronal para enfermedades neurodegenerativas, incluidas la ELA y la EM.
클린(CLS: CLNN)는 경영진이 Benchmark 14th Annual Discovery One-on-One Investor Conference에 참여하고 2025년 12월 4일에 뉴욕, 뉴욕에서 투자자 1:1 미팅을 주최할 것이라고 발표했습니다. 미팅은 Benchmark 대표를 통해 예약제로 진행됩니다. 이 회사와 그 자회사 Clene Nanomedicine은 미토콘드리아 건강과 신경 보호에 초점을 맞추고 있으며, 신경퇴행성 질환인 ALS와 MS를 포함합니다.
Clene (Nasdaq: CLNN) a annoncé que la direction participera à la Benchmark 14th Annual Discovery One-on-One Investor Conference et organisera des entretiens individuels avec les investisseurs le 4 décembre 2025 à New York, New York. Les rencontres se feront sur rendez-vous via les représentants de Benchmark. L'entreprise et sa filiale Clene Nanomedicine se concentrent sur la santé mitochondriale et la protection neuronale pour les maladies neurodégénératives, notamment la SLA et la SEP.
Clene (Nasdaq: CLNN) gab bekannt, dass das Management an der Benchmark 14th Annual Discovery One-on-One Investor Conference teilnehmen und am 4. Dezember 2025 in New York, New York 1-zu-1-Investorenmeetings abhalten wird. Die Meetings erfolgen nach Vereinbarung über die Vertreter von Benchmark. Das Unternehmen und seine Tochtergesellschaft Clene Nanomedicine konzentrieren sich auf die mitochondriale Gesundheit und den neuronalen Schutz bei neurodegenerativen Erkrankungen, einschließlich ALS und MS.
كلين (ناسداك: CLNN) أعلنت الإدارة أنها ستشارك في Benchmark 14th Annual Discovery One-on-One Investor Conference وتستضيف لقاءات استثمارية ثنائية الاتجاه 1×1 في 4 ديسمبر 2025 في نيويورك، نيويورك. الاجتماعات تتم عن طريق التعيين من خلال ممثلي Benchmark. تركز الشركة وشركتها الفرعية Clene Nanomedicine على صحة الميتوكوندريا وحماية الخلايا العصبية لأمراض أعصاب تنكسية، بما في ذلك ALS وMS.
- None.
- None.
SALT LAKE CITY, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will participate at the Benchmark 14th Annual Discovery One-on-One Investor Conference by hosting 1x1 investor meetings.
Conference Details
Date: December 4, 2025
Location: New York, New York
Format: 1x1 meetings (contact your Benchmark Representative)
About Clene
Clene Inc., (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis. CNM-Au8® is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8® is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.clene.com or follow us on X (formerly Twitter) and LinkedIn.
Investor Contact
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com
617-283-2856
FAQ
When will Clene (CLNN) meet investors at the Benchmark conference?
How can investors schedule a 1x1 meeting with Clene (CLNN) at the Benchmark conference?
Where is the Benchmark 14th Annual Discovery One-on-One Investor Conference taking place for Clene (CLNN)?
What will Clene (CLNN) management discuss at the Benchmark investor meetings?
Is the Clene (CLNN) presentation at Benchmark open to the public or by appointment only?
Which Clene entity is attending the Benchmark conference under the CLNN ticker?
